“…Patients with GBS-like presentation who relapse shortly after treatment are classified as relapsing GBS (with treatment-related fluctuations), whereas those who deteriorate or relapse beyond 8 weeks from onset are classified as acute-onset CIDP [27]. Similar to those associated with membranous glomerulonephritis [9][10][11][12][13][14][15][16][17][18] and minimal change nephrotic syndrome [19][20][21][22], the neurologic presentations of previously reported cases of FSGS occurring in association with inflammatory neuropathies are diverse. These cases include patients with monophasic disease, like GBS [3,5,6], and those with a relapsing course, including CIDP [2,4,7,8] and relapsing GBS [1], suggesting heterogeneity in the time course and severity of neuropathy in these patients.…”